Literature DB >> 34687637

Alzheimer's disease associated with Down syndrome: a genetic form of dementia.

Juan Fortea1, Shahid H Zaman2, Sigan Hartley3, Michael S Rafii4, Elizabeth Head5, Maria Carmona-Iragui6.   

Abstract

Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's disease and are at very high risk of developing early-onset dementia, which is now the leading cause of death in this population. Diagnosis of dementia remains a clinical challenge because of the lack of validated diagnostic criteria in this population, and because symptoms are overshadowed by the intellectual disability associated with Down syndrome. In people with Down syndrome, fluid and imaging biomarkers have shown good diagnostic performances and a strikingly similar temporality of changes with respect to sporadic and autosomal dominant Alzheimer's disease. Most importantly, there are no treatments to prevent Alzheimer's disease, even though adults with Down syndrome could be an optimal population in whom to conduct Alzheimer's disease prevention trials. Unprecedented research activity in Down syndrome is rapidly changing this bleak scenario that will translate into disease-modifying therapies that could benefit other populations.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34687637      PMCID: PMC9387748          DOI: 10.1016/S1474-4422(21)00245-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   59.935


  112 in total

1.  Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study.

Authors:  Yakeel T Quiroz; Henrik Zetterberg; Eric M Reiman; Yinghua Chen; Yi Su; Joshua T Fox-Fuller; Gloria Garcia; Andres Villegas; Diego Sepulveda-Falla; Marina Villada; Joseph F Arboleda-Velasquez; Edmarie Guzmán-Vélez; Clara Vila-Castelar; Brian A Gordon; Stephanie A Schultz; Hillary D Protas; Valentina Ghisays; Margarita Giraldo; Victoria Tirado; Ana Baena; Claudia Munoz; Silvia Rios-Romenets; Pierre N Tariot; Kaj Blennow; Francisco Lopera
Journal:  Lancet Neurol       Date:  2020-05-26       Impact factor: 44.182

2.  A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome.

Authors:  M McCarron; P McCallion; E Reilly; P Dunne; R Carroll; N Mulryan
Journal:  J Intellect Disabil Res       Date:  2017-06-29

3.  Clinical and EEG features of seizures in adults with down syndrome.

Authors:  Stela Lefter; Daniel J Costello; Brian McNamara; Brian Sweeney
Journal:  J Clin Neurophysiol       Date:  2011-10       Impact factor: 2.177

4.  Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.

Authors:  Adam S Fleisher; Kewei Chen; Yakeel T Quiroz; Laura J Jakimovich; Madelyn Gutierrez Gomez; Carolyn M Langois; Jessica B S Langbaum; Auttawut Roontiva; Pradeep Thiyyagura; Wendy Lee; Napatkamon Ayutyanont; Liliana Lopez; Sonia Moreno; Claudia Muñoz; Victoria Tirado; Natalia Acosta-Baena; Anne M Fagan; Margarita Giraldo; Gloria Garcia; Matthew J Huentelman; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  JAMA Neurol       Date:  2015-03       Impact factor: 18.302

5.  Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

Authors:  C A Lemere; J K Blusztajn; H Yamaguchi; T Wisniewski; T C Saido; D J Selkoe
Journal:  Neurobiol Dis       Date:  1996-02       Impact factor: 5.996

6.  The pathological association between Down syndrome and Alzheimer disease.

Authors:  D M Mann
Journal:  Mech Ageing Dev       Date:  1988-05       Impact factor: 5.432

7.  Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.

Authors:  A M Cataldo; C M Peterhoff; J C Troncoso; T Gomez-Isla; B T Hyman; R A Nixon
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 8.  Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis.

Authors:  María Carmona-Iragui; Laura Videla; Alberto Lleó; Juan Fortea
Journal:  Dev Neurobiol       Date:  2019-08-05       Impact factor: 3.964

Review 9.  Intracerebral haemorrhage in Down syndrome: protected or predisposed?

Authors:  Lewis Buss; Elizabeth Fisher; John Hardy; Dean Nizetic; Jurgen Groet; Laura Pulford; André Strydom
Journal:  F1000Res       Date:  2016-05-12

Review 10.  The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology.

Authors:  Benjamin L Handen; Ira T Lott; Bradley T Christian; Nicole Schupf; Sid OBryant; Mark Mapstone; Anne M Fagan; Joseph H Lee; Dana Tudorascu; Mei-Cheng Wang; Elizabeth Head; William Klunk; Beau Ances; Florence Lai; Shahid Zaman; Sharon Krinsky-McHale; Adam M Brickman; H Diana Rosas; Annie Cohen; Howard Andrews; Sigan Hartley; Wayne Silverman
Journal:  Alzheimers Dement (Amst)       Date:  2020-08-03
View more
  16 in total

Review 1.  The Hole-Board Test in Mutant Mice.

Authors:  Robert Lalonde; Catherine Strazielle
Journal:  Behav Genet       Date:  2022-04-28       Impact factor: 2.805

2.  Commentary on Oeckl et al., "Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181".

Authors:  Elizabeth Head; Henrik Zetterberg
Journal:  Ann Neurol       Date:  2022-06-02       Impact factor: 11.274

Review 3.  Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches.

Authors:  Clíona Farrell; Paige Mumford; Frances K Wiseman
Journal:  Front Neurosci       Date:  2022-06-07       Impact factor: 5.152

4.  Involvement of the HERV-derived cell-fusion inhibitor, suppressyn, in the fusion defects characteristic of the trisomy 21 placenta.

Authors:  Jun Sugimoto; Danny J Schust; Tomomi Yamazaki; Yoshiki Kudo
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

5.  Will SARS-COV-2 infection accelerate the incidence of Alzheimer's disease in Down syndrome population?

Authors:  Anita Barišić; Jadranka Vraneković
Journal:  Aging Clin Exp Res       Date:  2022-10-21       Impact factor: 4.481

6.  Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome.

Authors:  Maria Florencia Iulita; Diana Garzón Chavez; Maria Klitgaard Christensen; Natalia Valle Tamayo; Oleguer Plana-Ripoll; Sonja A Rasmussen; Marta Roqué Figuls; Daniel Alcolea; Laura Videla; Isabel Barroeta; Bessy Benejam; Miren Altuna; Concepción Padilla; Jordi Pegueroles; Susana Fernandez; Olivia Belbin; María Carmona-Iragui; Rafael Blesa; Alberto Lleó; Alexandre Bejanin; Juan Fortea
Journal:  JAMA Netw Open       Date:  2022-05-02

7.  Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study.

Authors:  Concepcion Padilla; Victor Montal; Madeleine J Walpert; Young T Hong; Tim D Fryer; Jonathan P Coles; Franklin I Aigbirhio; Sigan L Hartley; Ann D Cohen; Dana L Tudorascu; Bradley T Christian; Benjamin L Handen; William E Klunk; Anthony J Holland; Shahid H Zaman
Journal:  Alzheimers Dement (Amst)       Date:  2022-04-01

8.  Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer's Disease.

Authors:  Sandra Giménez; Ariadna Farre; Fátima Morente; Laura Videla; Marta Gutiérrez; Susana Clos; Ana Fernández; Marta Blanco; Miren Altuna; Jordi Pegueroles; Amparo Asensio; Bessy Benejam; Mar Batista; Isabel Barroeta; Ana Fortuna; Juan Fortea; Mercedes Mayos
Journal:  Front Neurosci       Date:  2022-03-30       Impact factor: 4.677

Review 9.  Dissecting the clinical heterogeneity of early-onset Alzheimer's disease.

Authors:  Daniel W Sirkis; Luke W Bonham; Taylor P Johnson; Renaud La Joie; Jennifer S Yokoyama
Journal:  Mol Psychiatry       Date:  2022-04-07       Impact factor: 13.437

10.  Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21.

Authors:  Paige Mumford; Justin Tosh; Silvia Anderle; Eleni Gkanatsiou Wikberg; Gloria Lau; Sue Noy; Karen Cleverley; Takashi Saito; Takaomi C Saido; Eugene Yu; Gunnar Brinkmalm; Erik Portelius; Kaj Blennow; Henrik Zetterberg; Victor Tybulewicz; Elizabeth M C Fisher; Frances K Wiseman
Journal:  J Neurosci       Date:  2022-07-14       Impact factor: 6.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.